Jetstream Venture Fund, an innovative interval fund focused on opening access to institutional-grade deal flow, has announced a strategic investment in Rejuvenation Technologies. The biotechnology company is pioneering targeted mRNA therapies designed to extend telomeres and restore cellular regenerative capacity in severe age-related diseases. This investment reinforces Jetstream's growing presence in longevity science, life extension, and advanced gene therapy while broadening opportunities for everyday investors who are seeking exposure to transformative biomedical innovation.
A Strategic Investment in Longevity Science
Jetstream structured this investment to gain early-stage exposure to a company that is addressing critical treatment gaps in the regenerative medicine sector. Rejuvenation Technologies is developing therapies that could meaningfully change how physicians treat chronic, age-related conditions in the future. By adding this opportunity to its portfolio, the fund aims to provide mainstream investors with access to highly technical science that has traditionally been limited to institutional backers and specialized venture capital networks.
Rejuvenation Technologies' mRNA Platform
The company's therapeutic approach originated from foundational research conducted at Stanford University under the leadership of CEO and co-inventor Dr. John Ramunas. It relies on modified messenger RNA delivered through proprietary lipid nanoparticles to target specific organs and temporarily extend telomeres. Unlike permanent telomerase activation, this transient method is designed to reverse years of cellular aging in a single day without causing irreversible genetic modification or long-term genomic changes.
Expanding a Cohesive Portfolio
Rejuvenation Technologies joins recent Jetstream portfolio additions Rejuvenate Bio and Wonderlab Bio, creating a cohesive group focused on human healthspan and cellular repair. Rejuvenate Bio is a Harvard-spun gene therapy company backed by Merck Animal Health, while Wonderlab Bio is a pioneer in off-the-shelf cell therapies. Together these three investments form a high-growth portfolio that grants retail investors exposure to the future of regenerative medicine and longevity-focused innovation.
Scientific Origins and Institutional Backing
Rejuvenation Technologies has attracted support from several top-tier institutional investors, including Khosla Ventures and Y Combinator, that specialize in early-stage science. The company has also secured more than $8 million in non-dilutive grants from the National Institutes of Health and the California Institute for Regenerative Medicine. This blend of private backing and public research funding supports a team that is advancing highly original science toward clinical applications in liver and lung diseases.
Preclinical Pipeline and Target Indications
The company is rapidly advancing preclinical programs that target idiopathic pulmonary fibrosis and severe chronic liver disease, two areas with urgent clinical demand. These conditions are associated with significant unmet medical need, substantial healthcare burdens worldwide, and limited treatment options for many patients. By focusing on telomere restoration, Rejuvenation Technologies is pursuing a mechanism that addresses a root cause of cellular decline rather than only managing symptoms after disease progression.
Executive Perspective
Chris Yoo, Fund Manager at Jetstream, emphasized that Rejuvenation Technologies represents the kind of highly technical, paradigm-shifting science the fund seeks to identify early. He noted that adding the company's breakthrough mRNA platform alongside existing stakes in Rejuvenate Bio and Wonderlab Bio gives investors a seat at the table for disruptive technologies. Yoo added that such approaches could fundamentally alter how chronic, age-related diseases are treated across multiple medical specialties.
Jetstream's investment in Rejuvenation Technologies underscores a broader effort to make venture capital opportunities in advanced biotechnology more accessible to everyday investors. The fund continues to identify early-stage companies that combine rigorous scientific expertise with the potential for significant medical and commercial impact. As its longevity portfolio expands, Jetstream aims to offer diversified exposure to therapies that may shape the future of human health and extend healthy lifespan.